# Cancer Centers Deep Research Report
## For RISA Labs AI Go-To-Market Strategy

*Compiled: February 20, 2026*

---

# 1. TEXAS ONCOLOGY

**Type:** Largest physician-owned community oncology practice in the US
**Website:** https://www.texasoncology.com/
**Parent Network:** US Oncology (owned by McKesson Corporation since 2010, $2.16B acquisition)

---

## A. Cancer Sub-types Treated

**Broad Coverage â€” Virtually All Solid & Hematologic Malignancies:**
- **Breast Cancer** â€” Major focus; Texas Breast Specialists is a dedicated sub-brand
- **Lung Cancer** â€” Surgery, chemo, immunotherapy
- **Prostate Cancer** â€” All-stage treatment
- **Skin Cancer / Melanoma** â€” Including surgical
- **Colorectal Cancer** â€” Texas Colon & Rectal Specialists sub-brand
- **Gynecologic Oncology** â€” Ovarian, uterine, cervical, vulvar
- **Hematology / Blood Cancers** â€” Leukemia, lymphoma, myeloma, blood disorders
- **Urologic Cancers** â€” Texas Urology Specialists sub-brand
- **GI, Head & Neck, Brain, Sarcoma, etc.** â€” Full community oncology coverage

**Unique Specializations:**
- **Proton Therapy** â€” Operates proton therapy centers (capital-intensive, differentiating)
- **Precision Medicine / Genomics** â€” Genetic, environmental, and lifestyle data for personalized treatment
- **Community-Based Model** â€” Bringing academic-grade care to rural/underserved Texas communities
- **Enhancing Oncology Model (EOM)** â€” Selected CMS participant for value-based care

**Note:** As a community practice, they do NOT typically treat ultra-rare cancers or perform complex transplants â€” those get referred to academic medical centers.

## B. Revenue / Financial Profile

| Metric | Data |
|---|---|
| **Physicians** | 550+ (460+ oncologists + specialists) |
| **Locations** | 250â€“300+ across Texas, plus offices in NM and OK |
| **Patients Treated Annually** | 68,000+ |
| **Estimated Revenue** | $2â€“3B+ (estimated; private, not disclosed separately from McKesson) |
| **Parent** | McKesson Specialty Health / US Oncology Network |
| **Founded** | 1986 at Baylor University Medical Center, Dallas |
| **EHR** | iKnowMed (US Oncology's proprietary EHR via McKesson) |

**Financial Structure:**
- Physician-owned practice, but McKesson/US Oncology provides management services (billing, IT, operations, GPO purchasing)
- Revenue from commercial insurance, Medicare, Medicaid
- Drug revenue is substantial (buy-and-bill model for infused chemotherapy)
- Part of the US Oncology Network (~1,400 physicians nationally)
- NOT a nonprofit â€” no 990 filings. Financial data is embedded within McKesson's SEC filings under Specialty Health segment
- McKesson's US Pharmaceutical segment: ~$300B+ revenue; oncology is a high-margin specialty subsegment

**Key Financial Insight:** Community oncology is under massive margin pressure from payer denials, 340B competition, biosimilar adoption, and CMS reimbursement changes. Texas Oncology's scale is its moat.

## C. Oncologist Sub-types

**550+ Physicians across these specialties:**

| Specialty | Presence |
|---|---|
| Medical Oncology | âœ… Core â€” largest group |
| Hematology / Heme-Onc | âœ… Significant |
| Radiation Oncology | âœ… Across many sites |
| Surgical Oncology | âœ… Texas Oncology Surgical Specialists |
| Gynecologic Oncology | âœ… Dedicated program |
| Breast Surgery | âœ… Texas Breast Specialists |
| Urology | âœ… Texas Urology Specialists |
| Colorectal Surgery | âœ… Texas Colon & Rectal Specialists |
| Palliative Medicine | âœ… |
| Pediatric Heme-Onc | âœ… Limited |

**Leadership:**
- Management through US Oncology Network / McKesson
- Practice is physician-governed with a managing physician board
- Notable for having a large Advanced Practice Provider (APP) workforce (NPs, PAs)

## D. AI Use-Case Mapping

| RISA Labs Vertical | Opportunity | Rationale |
|---|---|---|
| **Patient Access AI** | ðŸ”´ **HIGH** | 250+ locations = massive scheduling complexity. Prior auth for chemo drugs is a nightmare. Insurance verification across dozens of payers. Referral management from PCPs across Texas. This is THE pain point for community oncology. |
| **RCM AI** | ðŸ”´ **HIGH** | Buy-and-bill model means drug coding and charge capture is extremely complex. Denials on oncology drugs (J-codes, NDC crosswalks) are epidemic. McKesson provides back-office but practices still leak revenue. Claims volume is enormous at 68K+ patients/year. |
| **Clinical AI** | ðŸŸ¡ **MEDIUM** | They use iKnowMed EHR with built-in pathways (Via Oncology/NCCN). Clinical trial matching is relevant (US Oncology Research runs 100+ trials). Less need for tumor board AI (community model). Treatment planning standardization is a fit. |
| **Life Sciences** | ðŸŸ¡ **MEDIUM** | US Oncology Research arm runs Phase I-IV trials. Real-world data from 68K+ patients is valuable to pharma. McKesson already monetizes some of this through Ontada (their data/analytics subsidiary). Opportunity exists but competes with Ontada. |

**Key Insight:** Patient Access and RCM are the slam-dunk entry points. Texas Oncology's scale makes even small per-encounter efficiency gains worth millions.

---

# 2. STANFORD CANCER INSTITUTE / STANFORD CANCER CENTER

**Type:** NCI-designated Comprehensive Cancer Center (academic medical center)
**Website:** https://med.stanford.edu/cancer
**Part of:** Stanford University School of Medicine & Stanford Health Care

---

## A. Cancer Sub-types Treated

**Full Spectrum â€” All Cancer Types Including Rare and Complex:**

**Six Research Programs Define Their Focus:**
1. **Cancer Cell Biology** â€” Molecular mechanisms, cancer stem cells
2. **Cancer Imaging and Early Detection** â€” Novel imaging, liquid biopsy
3. **Cancer Immunotherapy** â€” CAR-T, checkpoint inhibitors, vaccine development
4. **Cancer Therapeutics** â€” Translational drug development
5. **Population Sciences** â€” Epidemiology, prevention, disparities
6. **Radiation Biology** â€” Advanced radiotherapy techniques

**Clinical Centers of Excellence:**
- **Hematologic Malignancies / BMT** â€” World-class stem cell transplant program
- **Immunotherapy** â€” Pioneer in CAR-T; Irving Weissman (cancer stem cell pioneer) was founding director
- **Precision Genomics** â€” Stanford has massive sequencing infrastructure
- **Neuro-Oncology** â€” Stanford neurosurgery is top-ranked
- **Pediatric Oncology** â€” Lucile Packard Children's Hospital
- **Prostate / GU Oncology** â€” Strong surgical robotics program
- **Thoracic Oncology** â€” Lung cancer screening and intervention
- **Rare Cancers** â€” Academic centers are referral destinations for rare tumors

**Unique Differentiators:**
- Founding member of NCCN (National Comprehensive Cancer Network)
- 250+ actively recruiting clinical trials
- Silicon Valley location â†’ deep tech/AI ecosystem connections
- Stanford HAI (Human-Centered AI) integration potential

## B. Revenue / Financial Profile

| Metric | Data |
|---|---|
| **Faculty Members** | 300+ cancer-focused within Stanford network |
| **NCI Designation** | Comprehensive Cancer Center (since 2016; renewed 2022) |
| **Clinical Trials** | 250+ actively recruiting |
| **Stanford Health Care Revenue** | ~$12â€“14B total system (cancer is a major service line) |
| **Stanford Cancer Center Revenue** | Estimated $1.5â€“2.5B (not broken out separately) |
| **Locations** | Main campus (Palo Alto) + Stanford Cancer Center South Bay + satellite clinics |
| **Director** | Steven Artandi, MD, PhD (since 2018) |
| **EHR** | Epic |

**Financial Structure:**
- Stanford Health Care is a nonprofit (990 available)
- Major NCI Cancer Center Support Grant (CCSG) â€” typically $5â€“10M/year
- NIH research funding: Stanford School of Medicine is consistently top-5 nationally (~$600M+/year in NIH funding; cancer is a large share)
- Philanthropy is massive â€” Stanford endowment is ~$36B
- Patient revenue: commercial insurance mix is very favorable (Silicon Valley demographics = employer-sponsored coverage)
- Stanford Medicine is also investing heavily in AI â€” launched multiple AI health initiatives

## C. Oncologist Sub-types

**300+ Faculty Members:**

| Specialty | Presence |
|---|---|
| Medical Oncology | âœ… Large department |
| Hematology / BMT | âœ… World-class |
| Radiation Oncology | âœ… Strong research program |
| Surgical Oncology | âœ… Multiple sub-specialties |
| Gynecologic Oncology | âœ… |
| Neuro-Oncology | âœ… Strong |
| Pediatric Oncology | âœ… Packard Children's |
| Pathology / Molecular Diagnostics | âœ… Major |
| Radiology / Imaging | âœ… AI-forward imaging research |
| Palliative / Supportive Care | âœ… |
| Cancer Genetics / Genomics | âœ… Pioneer |

**Notable Leadership:**
- **Steven Artandi, MD, PhD** â€” Director, Stanford Cancer Institute (telomere biology expert)
- **Irving Weissman, MD** â€” Founding director, cancer stem cell pioneer
- **Beverly Mitchell, MD** â€” Former director (2008-2018)
- Deep bench of ASCO, AACR leadership figures

## D. AI Use-Case Mapping

| RISA Labs Vertical | Opportunity | Rationale |
|---|---|---|
| **Patient Access AI** | ðŸŸ¡ **MEDIUM** | Fewer locations but high complexity. Tertiary referrals from across the country need sophisticated intake. Prior auth for novel/experimental therapies is brutal. Stanford already has Epic + internal innovation teams â€” harder to sell to. |
| **RCM AI** | ðŸŸ¡ **MEDIUM** | Academic centers have complex billing (professional + facility + research). Denials on experimental therapies are common. But Stanford Health Care has robust rev cycle teams already. Opportunity in specialty-specific coding accuracy. |
| **Clinical AI** | ðŸ”´ **HIGH** | This is Stanford's sweet spot. Clinical decision support, genomic interpretation, clinical trials matching for 250+ trials, tumor board augmentation, pathology AI. Stanford is a natural early adopter and design partner. They already do AI research â€” partner, don't sell. |
| **Life Sciences** | ðŸ”´ **HIGH** | Massive pharma partnership ecosystem. Real-world evidence from complex patient cohorts. Biomarker discovery. Trial enrollment optimization for 250+ trials. This is where Stanford's academic data is gold. |

**Key Insight:** Stanford is a DESIGN PARTNER, not just a customer. Lead with Clinical AI and Life Sciences. They'll want to co-develop and publish, which gives RISA Labs credibility across all academic centers.

---

# 3. FRED HUTCHINSON CANCER CENTER (Fred Hutch)

**Type:** NCI-designated Comprehensive Cancer Center (independent nonprofit, research + clinical)
**Website:** https://www.fredhutch.org/
**Location:** Seattle, WA (South Lake Union campus, 16+ acres)
**Clinical Partner:** UW Medicine (Fred Hutch serves as the cancer program for UW Medicine)

---

## A. Cancer Sub-types Treated

**Full Spectrum with Distinctive Strengths:**

**Pioneering Specializations:**
- **Bone Marrow / Stem Cell Transplant (BMT)** â€” *THE* birthplace of BMT. E. Donnall Thomas won the 1990 Nobel Prize for pioneering this here. Still one of the world's leading transplant centers.
- **Immunotherapy / CAR-T** â€” Juno Therapeutics (now part of Bristol-Myers Squibb/Celgene) was spun out of Fred Hutch. Deep CAR-T expertise.
- **Hematologic Malignancies** â€” Leukemia, lymphoma, myeloma, MDS â€” historically the core strength
- **Infectious Disease & Cancer** â€” Unique program studying HIV-associated cancers, HPV, etc.
- **Global Oncology** â€” Research in 60+ countries

**Also Treats:**
- All solid tumors (lung, breast, prostate, GI, GU, etc.)
- Rare cancers
- Pediatric cancers (through Seattle Children's partnership)
- Sarcoma, neuro-oncology, head & neck

**3 Nobel Prize Winners:**
1. E. Donnall Thomas (1990) â€” Bone marrow transplantation
2. Leland H. Hartwell (2001) â€” Cell division mechanisms
3. Linda B. Buck (2004) â€” Olfactory system

## B. Revenue / Financial Profile

| Metric | Data |
|---|---|
| **Budget** | ~$654.6M (2020 reported); likely $800Mâ€“1B+ post-merger with SCCA (2022) |
| **Employees** | 6,000+ |
| **Campus** | 16+ acres, South Lake Union, Seattle |
| **NCI Designation** | Comprehensive Cancer Center (since 1976 â€” one of the original 15) |
| **Structure** | Independent 501(c)(3) nonprofit |
| **Clinical Integration** | Merged with Seattle Cancer Care Alliance (SCCA) in April 2022 |
| **UW Partnership** | Serves as cancer program for UW Medicine |
| **CEO/President** | Thomas Lynch Jr., MD |
| **EHR** | Epic (through UW Medicine integration) |
| **Auditor** | KPMG |
| **990 Preparer** | Clark Nuber, PS |

**Financial Structure:**
- **NCI Cancer Center Support Grant (CCSG)** â€” Major federal grant
- **NIH Funding** â€” Substantial; Fred Hutch is historically top-10 in NIH cancer funding
- **Philanthropy** â€” Significant donor base; annual giving campaigns
- **Clinical Revenue** â€” Post-SCCA merger, patient care revenue is now substantial
- **Technology Transfer** â€” Notable: Juno Therapeutics ($314M VC + $265M IPO from Fred Hutch IP); ~20 spinout companies since 1975 (including Immunex, Icos)
- **FY25 Audited Financial Statement** available on their website

## C. Oncologist Sub-types

**Hundreds of faculty across research and clinical:**

| Specialty | Presence |
|---|---|
| Medical Oncology | âœ… |
| Hematology / BMT | âœ… World-leading |
| Radiation Oncology | âœ… Through UW Medicine |
| Surgical Oncology | âœ… Through UW Medicine |
| Immunotherapy / Cell Therapy | âœ… Pioneer |
| Infectious Disease Oncology | âœ… Unique niche |
| Pediatric Oncology | âœ… Through Seattle Children's |
| Cancer Prevention / Population Sciences | âœ… |
| Basic Science / Cancer Biology | âœ… Very large research faculty |
| Pathology | âœ… |

**Notable Leadership:**
- **Thomas Lynch Jr., MD** â€” President/Director (since 2020)
- **H. Joachim Deeg** â€” Pioneered BMT for MDS
- Deep bench of HHMI investigators, NAS members

## D. AI Use-Case Mapping

| RISA Labs Vertical | Opportunity | Rationale |
|---|---|---|
| **Patient Access AI** | ðŸŸ¡ **MEDIUM** | Complex referral patterns (patients come nationally/internationally for BMT). Integration complexity between Fred Hutch and UW Medicine systems. Prior auth for transplant and CAR-T is extremely complex and high-value. Fewer total patients than TX Onc but higher complexity per case. |
| **RCM AI** | ðŸŸ¡ **MEDIUM** | BMT and CAR-T billing is among the most complex in all of medicine (6-figure claims, multi-month episodes). Denials on transplant authorizations are devastating. Opportunity is high-value but niche. Post-merger SCCA integration may have created billing complexity. |
| **Clinical AI** | ðŸ”´ **HIGH** | Clinical trials matching is critical â€” they run extensive trials. Treatment planning for BMT/CAR-T is complex. Genomic interpretation for hematologic malignancies. Tumor board support. Real-time clinical decision support for transplant complications. |
| **Life Sciences** | ðŸ”´ **HIGH** | This is Fred Hutch's DNA. They spun out Juno Therapeutics. Massive biobank. Real-world evidence from decades of BMT data. Pharma partnerships for cell therapy, immunotherapy. Biomarker programs. Clinical trial enrollment optimization. They are a data-rich institution looking to monetize IP. |

**Key Insight:** Fred Hutch is the ideal Life Sciences AI partner. Their research-to-clinic pipeline is extraordinary. Clinical AI for trial matching and complex treatment planning is the clinical entry point. The SCCA merger created operational integration challenges that Patient Access and RCM AI could address.

---

# E. 100 Cancer Center Workflows

## Front Office / Patient Access (WF1â€“WF20)

| # | Workflow |
|---|---|
| WF1 | New patient appointment scheduling (matching cancer type â†’ right oncologist â†’ right location) |
| WF2 | Insurance eligibility verification (real-time payer check at registration) |
| WF3 | Prior authorization for chemotherapy drugs (oral and infused) |
| WF4 | Prior authorization for radiation therapy treatment plans |
| WF5 | Prior authorization for PET/CT and advanced imaging |
| WF6 | Prior authorization for surgical procedures |
| WF7 | Referral intake and triage (PCP/specialist referrals, fax processing) |
| WF8 | Patient demographic registration and MRN creation |
| WF9 | New patient medical records collection (from outside facilities) |
| WF10 | Financial counseling and cost estimation for treatment plans |
| WF11 | Patient assistance program enrollment (copay assistance, manufacturer programs) |
| WF12 | Second opinion coordination (records collection, physician scheduling) |
| WF13 | Multi-visit appointment scheduling (chemo cycles, radiation series) |
| WF14 | Provider template management and capacity optimization |
| WF15 | Patient no-show/cancellation follow-up and rescheduling |
| WF16 | Pre-visit planning (ensuring labs, imaging ready before appointment) |
| WF17 | Patient portal enrollment and activation |
| WF18 | Out-of-network single-case agreement negotiation |
| WF19 | Transfer/referral to academic center for complex cases |
| WF20 | Interpreter/language services scheduling |

## Clinical Operations (WF21â€“WF40)

| # | Workflow |
|---|---|
| WF21 | Infusion chair scheduling and optimization (chair time allocation) |
| WF22 | Chemotherapy order verification and pharmacy preparation |
| WF23 | Nurse triage of patient phone calls (symptom management) |
| WF24 | Lab order management and results routing |
| WF25 | Imaging order coordination (scheduling, prior auth, results) |
| WF26 | Pharmacy benefit verification for oral oncolytics |
| WF27 | Specialty pharmacy coordination for oral chemo |
| WF28 | Drug inventory management and 340B split-billing |
| WF29 | Chemotherapy regimen protocol management and updates |
| WF30 | Patient vitals and pre-treatment assessment |
| WF31 | Infusion reaction monitoring and documentation |
| WF32 | Blood product ordering and transfusion management |
| WF33 | Central line/port placement scheduling and care |
| WF34 | Radiation treatment planning (simulation, dosimetry, QA) |
| WF35 | Daily radiation treatment delivery and documentation |
| WF36 | Surgical scheduling and pre-op clearance coordination |
| WF37 | Pathology specimen tracking and results management |
| WF38 | Genetic/genomic testing ordering and results interpretation |
| WF39 | Patient education material distribution (treatment-specific) |
| WF40 | After-hours on-call triage and ED diversion |

## Revenue Cycle (WF41â€“WF60)

| # | Workflow |
|---|---|
| WF41 | Professional fee coding (E&M, chemo admin, procedures) |
| WF42 | Facility/technical charge capture |
| WF43 | Drug charge capture (J-codes, NDC crosswalk, ASP-based pricing) |
| WF44 | Claim generation and submission (837P/837I) |
| WF45 | Claim status inquiry and follow-up (276/277) |
| WF46 | Denial identification and categorization |
| WF47 | Denial appeal writing and submission |
| WF48 | Payment posting (ERA/835 processing) |
| WF49 | Patient statement generation and mailing |
| WF50 | Patient collections and payment plan setup |
| WF51 | Underpayment identification and payer recovery |
| WF52 | Credit balance resolution |
| WF53 | Charge reconciliation (orders vs. charges vs. claims) |
| WF54 | Drug reimbursement optimization (ASP, WAC, 340B) |
| WF55 | Radiation therapy technical billing (CPT code selection per fraction) |
| WF56 | Modifier application (59, 25, TC, 26, etc.) |
| WF57 | Clinical trial billing compliance (coverage analysis, routing) |
| WF58 | Workers' comp and auto accident claim processing |
| WF59 | Bad debt write-off and charity care determination |
| WF60 | Month-end revenue reconciliation and financial close |

## Clinical Care (WF61â€“WF80)

| # | Workflow |
|---|---|
| WF61 | New patient oncology consultation and treatment planning |
| WF62 | Multidisciplinary tumor board case preparation and presentation |
| WF63 | Treatment plan documentation and patient consent |
| WF64 | Chemotherapy order entry with dose calculation (BSA, renal function) |
| WF65 | Treatment response assessment (RECIST, imaging review) |
| WF66 | Clinical trial screening and eligibility determination |
| WF67 | Clinical trial enrollment and consent |
| WF68 | Clinical trial protocol compliance monitoring |
| WF69 | Adverse event grading and reporting (CTCAE) |
| WF70 | Survivorship care plan creation and delivery |
| WF71 | Palliative care consultation and goals-of-care discussion |
| WF72 | Hospice referral and transition of care |
| WF73 | Cancer genetics counseling and hereditary risk assessment |
| WF74 | Molecular tumor profiling (NGS panel ordering, results review) |
| WF75 | Biomarker-driven therapy selection |
| WF76 | Supportive care management (antiemetics, growth factors, pain) |
| WF77 | Care coordination with primary care and other specialists |
| WF78 | Patient-reported outcomes (PRO) collection and monitoring |
| WF79 | Distress screening and psychosocial support referral |
| WF80 | Advance care planning and documentation |

## Research / Life Sciences (WF81â€“WF90)

| # | Workflow |
|---|---|
| WF81 | Clinical trial feasibility assessment for new protocols |
| WF82 | IRB submission and regulatory approval |
| WF83 | Trial patient recruitment and pre-screening |
| WF84 | Informed consent documentation and tracking |
| WF85 | Case report form (CRF) data entry and query resolution |
| WF86 | Biospecimen collection, processing, and biobank management |
| WF87 | Adverse event and safety reporting to sponsor/FDA |
| WF88 | Real-world data abstraction from EHR for research |
| WF89 | Pharma partnership data sharing and contract management |
| WF90 | Investigator-initiated trial budget development and management |

## Back Office (WF91â€“WF100)

| # | Workflow |
|---|---|
| WF91 | Physician credentialing and payer enrollment |
| WF92 | Payer contract negotiation and fee schedule management |
| WF93 | Quality measure reporting (MIPS, OCM/EOM, QOPI) |
| WF94 | Compliance auditing (coding, documentation, HIPAA) |
| WF95 | Staff scheduling and workforce management |
| WF96 | Provider productivity tracking and compensation modeling |
| WF97 | Incident reporting and patient safety event management |
| WF98 | Drug purchasing and GPO contract management |
| WF99 | Facility/equipment maintenance and regulatory compliance |
| WF100 | Strategic planning and market analysis (service line growth) |

---

# F. Pain Points

## Universal Pain Points Across All Three Centers

### 1. Prior Authorization Hell ðŸ”¥ðŸ”¥ðŸ”¥
- **Severity: Critical** â€” #1 pain point in oncology
- Average 40+ hours/week per practice spent on prior auth (ASCO surveys)
- Chemo drugs, imaging, genomic tests, and procedures ALL require PA
- Delays cause treatment delays â†’ worse outcomes â†’ liability risk
- Step therapy and fail-first protocols force patients onto cheaper drugs first
- **Texas Oncology impact:** Multiplied by 250+ sites = thousands of PA requests daily
- **Stanford impact:** Novel/experimental therapies have even higher denial rates
- **Fred Hutch impact:** BMT and CAR-T prior auth can take weeks; $500K+ per case

### 2. Denials & Revenue Leakage ðŸ”¥ðŸ”¥ðŸ”¥
- **Severity: Critical**
- Oncology has among the highest denial rates of any specialty (15-25% initial denial rate)
- Drug denials (wrong J-code, NDC mismatch, medical necessity) are epidemic
- Many practices write off 3-5% of net revenue to preventable denials
- Appeals are manual, time-consuming, and often not pursued
- **Texas Oncology:** At $2B+ revenue, even 1% leakage = $20M+ annually
- **Stanford/Fred Hutch:** Complex cases = higher per-claim value at risk

### 3. Staffing Shortages & Burnout ðŸ”¥ðŸ”¥
- **Severity: High**
- Oncology nursing shortage is acute nationwide
- Prior auth staff, coders, and billers are in short supply
- Physician burnout from documentation burden (pajama time on EHR)
- APP (NP/PA) roles expanding to fill physician gaps
- **Texas Oncology:** Rural Texas locations struggle most with recruitment
- **Academic centers:** Compete for talent with tech companies (especially Stanford in Silicon Valley)

### 4. EHR Frustration ðŸ”¥ðŸ”¥
- **Severity: High**
- Texas Oncology uses iKnowMed (McKesson) â€” functional but dated, limited interoperability
- Stanford and Fred Hutch use Epic â€” powerful but complex, click-heavy
- Oncology workflows don't fit neatly into general EHR designs
- Treatment plan documentation is cumbersome
- Clinical trial documentation in EHR is a square-peg-round-hole problem

### 5. Clinical Trial Enrollment Bottlenecks ðŸ”¥ðŸ”¥
- **Severity: High**
- Only 3-5% of adult cancer patients enroll in clinical trials
- Screening for eligibility across hundreds of criteria is manual
- Patients don't know what trials are available
- **Stanford (250+ trials):** Matching patients to the right trial is a needle-in-haystack problem
- **Fred Hutch:** Same challenge, especially for rare diseases
- **Texas Oncology:** Community sites often don't have trial awareness; US Oncology Research runs trials but enrollment lags

### 6. Care Coordination Complexity ðŸ”¥ðŸ”¥
- **Severity: High**
- Cancer care involves 6-12 different specialties per patient
- Records transfer between facilities is still largely fax-based
- Transition from active treatment â†’ survivorship â†’ palliative â†’ hospice is poorly coordinated
- **Texas Oncology:** 250+ sites means internal coordination is challenging
- **Fred Hutch:** Fred Hutch + UW Medicine integration post-merger adds complexity

### 7. Patient Access & Wait Times ðŸ”¥
- **Severity: Moderate-High**
- New patient appointments can take 2-4 weeks at academic centers
- Rural Texas patients travel hours for treatment
- Scheduling complexity for multi-modal therapy (surgery + chemo + radiation)
- **Stanford:** Wait times for consults can be weeks due to demand
- **Texas Oncology:** Better access due to distributed model, but scheduling across 250+ sites is complex

### 8. Drug Cost & Access ðŸ”¥
- **Severity: Moderate-High**
- Oral oncolytic costs are staggering ($10K-20K/month)
- Specialty pharmacy coordination is a full-time job
- 340B program complexity and compliance burden
- Biosimilar adoption and payer steering create confusion

---

# G. Demo Recommendations for RISA Labs

## Demo Strategy for Texas Oncology

### ðŸŽ¯ The Hook
*"We can save your prior auth team 60% of their time and recover $15-20M in annual revenue leakage across your 250+ sites."*

### Best Demo Workflow
**Prior Authorization Automation + Denial Prevention**
- Show: AI reads a chemo order â†’ auto-generates PA request with clinical documentation â†’ submits electronically â†’ tracks status â†’ flags likely denials before submission
- Show: Dashboard across all 250+ sites with PA status, turnaround times, approval rates by payer
- Show: Denial prediction model that flags claims likely to be denied BEFORE submission, with suggested documentation fixes

### Buyer Personas
| Persona | Title | What They Care About |
|---|---|---|
| **Primary** | VP Revenue Cycle / CFO | Revenue recovery, denial reduction, staff efficiency |
| **Secondary** | VP Operations / COO | Operational efficiency across 250+ sites, standardization |
| **Clinical Champion** | Managing Physician / CMO | Reduced treatment delays from PA, less admin burden on physicians |
| **IT Gatekeeper** | CIO (McKesson/US Oncology level) | Integration with iKnowMed, security, scalability |

### Getting the Meeting
- Approach through McKesson/US Oncology Network leadership (they control IT decisions)
- Quantify the ROI: "$X per site per year in recovered revenue and reduced FTEs"
- Reference EOM participation â€” value-based care alignment
- Offer a pilot at 5-10 high-volume sites with clear success metrics

---

## Demo Strategy for Stanford Cancer Institute

### ðŸŽ¯ The Hook
*"We can match every new patient to the right clinical trial in under 60 seconds and help you publish the first AI-powered precision oncology trial matching study."*

### Best Demo Workflow
**Clinical Trial Matching + Genomic Decision Support**
- Show: Patient EHR data (genomic profile, staging, prior treatments) â†’ AI matches against 250+ active Stanford trials â†’ ranks by eligibility probability â†’ generates pre-screening summary for research coordinator
- Show: Integration with Stanford's precision medicine workflow â€” molecular tumor board augmentation
- Show: Real-world evidence dashboard aggregating outcomes data across their patient population

### Buyer Personas
| Persona | Title | What They Care About |
|---|---|---|
| **Primary** | Director, Stanford Cancer Institute (Steven Artandi) | Innovation, research impact, publications, NCI grant competitiveness |
| **Secondary** | VP Research / Associate Dean for Clinical Research | Trial enrollment rates, research operations efficiency |
| **Clinical Champion** | Disease-specific program leaders | Better patient-trial matching in their specialty |
| **Operations** | Chief Medical Officer, Stanford Health Care | Clinical quality, patient outcomes, competitive differentiation |

### Getting the Meeting
- Lead with ACADEMIC VALUE â€” co-development, publication opportunities, Stanford HAI alignment
- Reference other top NCI centers using AI for trial matching
- Offer to present at Stanford Cancer Institute seminar series
- Connect through Stanford HAI or Stanford Biomedical Informatics faculty
- Do NOT lead with cost savings â€” lead with research impact and patient outcomes

---

## Demo Strategy for Fred Hutchinson Cancer Center

### ðŸŽ¯ The Hook
*"We can accelerate your clinical trial enrollment by 3x and unlock the value of your decades of BMT and immunotherapy real-world data for pharma partnerships."*

### Best Demo Workflow
**Life Sciences Data Platform + Trial Enrollment Optimization**
- Show: AI-powered patient matching for BMT and cell therapy trials
- Show: Real-world evidence (RWE) platform that structures decades of Fred Hutch transplant outcomes data for pharma partnership use
- Show: Automated data abstraction from Epic â†’ structured research datasets â†’ FDA-grade evidence generation
- Bonus: Prior auth automation for BMT/CAR-T (where individual cases are $500K-1M and denial means catastrophic revenue loss)

### Buyer Personas
| Persona | Title | What They Care About |
|---|---|---|
| **Primary** | VP Research / Chief Scientific Officer | Accelerating discoveries, pharma partnerships, data monetization |
| **Secondary** | Thomas Lynch Jr. (President/CEO) | Strategic positioning, revenue diversification, innovation leadership |
| **Clinical Champion** | BMT/Cell Therapy program directors | Trial enrollment, treatment optimization, outcomes |
| **Operations** | CFO / VP Revenue Cycle | Post-merger SCCA integration, BMT billing complexity, denial recovery |
| **Industry** | VP Business Development / Technology Transfer | IP monetization, industry partnerships |

### Getting the Meeting
- Reference Juno Therapeutics story â€” "the next great Fred Hutch spinout could be powered by your data + our AI"
- Emphasize data sovereignty â€” Fred Hutch keeps control, RISA provides the tools
- Offer pilot on BMT/CAR-T trial matching (high-value, measurable)
- Connect through Fred Hutch's investors/industry collaboration team
- Seattle tech ecosystem angle â€” they're surrounded by Amazon, Microsoft, and understand AI

---

# Summary Comparison Matrix

| Dimension | Texas Oncology | Stanford Cancer Institute | Fred Hutch Cancer Center |
|---|---|---|---|
| **Type** | Community oncology network | Academic medical center | Research + clinical hybrid |
| **Scale** | 550+ physicians, 250+ sites, 68K patients/yr | 300+ faculty, few sites | 6,000+ employees, single campus |
| **Revenue** | Est. $2-3B+ | Est. $1.5-2.5B (cancer) | Est. $800M-1B+ |
| **Top AI Opportunity** | Patient Access + RCM | Clinical AI + Life Sciences | Life Sciences + Clinical AI |
| **Buyer** | CFO / VP Rev Cycle | Institute Director / VP Research | VP Research / CEO |
| **Best Demo** | Prior auth + denial prevention | Trial matching + genomics | RWE platform + trial enrollment |
| **Sales Cycle** | Enterprise (through McKesson) | Academic (slow, committee-driven) | Hybrid (research + operations) |
| **Integration** | iKnowMed (McKesson) | Epic | Epic |
| **Competitive Moat** | Scale + community access | Research prestige + NCI | BMT legacy + IP/spinout track |

---

*Sources: Texas Oncology website, Stanford Cancer Institute website & Wikipedia, Fred Hutchinson Cancer Center website & Wikipedia, McKesson SEC filings, NCI Cancer Center designations, ASCO survey data on prior auth burden, publicly available organizational data. Financial estimates are approximations based on available public data and industry benchmarks.*
